scholarly journals Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids

2018 ◽  
Vol 28 (11) ◽  
pp. 897-909 ◽  
Author(s):  
Craig M. McDonald ◽  
Heather Gordish-Dressman ◽  
Erik K. Henricson ◽  
Tina Duong ◽  
Nanette C. Joyce ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Natural History ◽  
Pulmonary Function ◽  
Outcome Measures ◽  
Pulmonary Function Testing ◽  
Function Testing

scholarly journals Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History

2018 ◽  
Vol 5 (1) ◽  
pp. 47-58 ◽  
Author(s):  
T. Bernard Kinane ◽  
Oscar H. Mayer ◽  
Petra W. Duda ◽  
Linda P. Lowes ◽  
Stephanie L. Moody ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Natural History ◽  
Pulmonary Function

Benign Tracheobronchial Stenoses: Changes in Short-Term and Long-Term Pulmonary Function Testing After Expandable Metallic Stent Placement

2002 ◽  
Vol 26 (4) ◽  
pp. 564-572 ◽  
Author(s):  
Michael B. Gotway ◽  
Jeffrey A. Golden ◽  
Jeanne M. LaBerge ◽  
W. Richard Webb ◽  
Gautham P. Reddy ◽  
...  
Keyword(s):  
Pulmonary Function ◽  
Stent Placement ◽  
Pulmonary Function Testing ◽  
Metallic Stent ◽  
Short Term ◽  
Expandable Metallic Stent ◽  
Function Testing ◽  
Metallic Stent Placement

COPD – Stellenwert der Lungenfunktionsanalyse in Diagnostik und Therapie

2018 ◽  
Vol 143 (08) ◽  
pp. 593-596 ◽  
Author(s):  
Wolfram Windisch ◽  
Carl Criée
Keyword(s):  
Pulmonary Function ◽  
Airway Obstruction ◽  
Pulmonary Emphysema ◽  
Pulmonary Function Testing ◽  
Exclusion Criterion ◽  
Chronic Obstructive ◽  
Pharmaceutical Treatment ◽  
Lung Hyperinflation ◽  
Function Testing

AbstractPulmonary function testing is essential for diagnosis and treatment-guidance of chronic obstructive pulmonary disease (COPD). Airway obstruction as assessed by spirometry should follow the reference-values provided by the Global Lung Initiative (GLI) of the European Respiratory Society (ERS). In addition, lung function testing should also include the assessment of lung hyperinflation and pulmonary emphysema by full-body plethysmography and determination of diffusion capacity. This is important since both, lung hyperinflation and pulmonary emphysema, can present without existing airway obstruction. Even though this formally excludes the diagnosis of COPD, these entities still belong to this disease complex. However, strictly speaking, pharmaceutical treatment is valid only for those patients with co-existing airway obstruction according to Global Lung Initiative for Chronic Obstructive Lung Disease (GOLD) criteria – since the absence of airway obstruction serves as exclusion criterion in nearly all randomized controlled trials. Nevertheless, progressive symptoms still require detailed pulmonary function testing for the guidance of non-pharmaceutical treatment – such as endoscopic or surgical lung volume reduction, long-term oxygen therapy, long-term non-invasive ventilation, and lung transplantation.

Sign in / Sign up

Export Citation Format

Share Document